Cas no 1233937-31-9 (Menaquinone 7-d7 (90%))
Menaquinone 7-d7 (90%) Chemical and Physical Properties
Names and Identifiers
-
- Menaquinone 7-d7
- 5,6,7,8-tetradeuterio-2-[(2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaenyl]-3-(trideuteriomethyl)naphthalene-1,4-dione
- (all-E)-2-(3,7,11,15,19,23,27-Heptamethyl-2,6,10,14,18,22,26-octacosaheptaenyl)-3-methyl-1,4-naphthalenedione-d7
- Menaquinone K7-d7
- Vitamin K2(35)-d7
- Vitamin MK 7-d7
- Menaquinone 7-d7 (100microg/mL in Acetonitrile) 90%
- CS-0202602
- Menaquinone-7-d7
- J-004933
- Vitamin K2 (MK-7)-(5,6,7,8-d4,2-methyl-d3), >=98 atom % D, >=95% (CP)
- 2-[(2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-Heptamethyloctacosa-2,6,10,14,18,22,26-heptaen-1-yl]-3-(~2~H_3_)methyl(~2~H_4_)naphthalene-1,4-dione
- DTXSID50857960
- (all-E)-2-(3,7,11,15,19,23,27-Heptamethyl-2,6,10,14,18,22,26-octacosaheptaenyl)-3-methyl-1,4-naphthalenedione-d7; Vitamin K2(35)-d7; Menaquinone K7-d7; Vitamin MK 7-d7;
- HY-112499S
- Menaquinone 7-d7 (90per cent)
- 1233937-31-9
- Menaquinone 7-d7 (90%)
-
- Inchi： 1S/C46H64O2/c1-34(2)18-12-19-35(3)20-13-21-36(4)22-14-23-37(5)24-15-25-38(6)26-16-27-39(7)28-17-29-40(8)32-33-42-41(9)45(47)43-30-10-11-31-44(43)46(42)48/h10-11,18,20,22,24,26,28,30-32H,12-17,19,21,23,25,27,29,33H2,1-9H3/b35-20+,36-22+,37-24+,38-26+,39-28+,40-32+/i9D3,10D,11D,30D,31D
- InChI Key： RAKQPZMEYJZGPI-HRQALKRPSA-N
- SMILES： O=C1C2C([2H])=C([2H])C([2H])=C([2H])C=2C(C(C([2H])([2H])[2H])=C1C/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/C)=O
Computed Properties
- Exact Mass: 655.53500
- Monoisotopic Mass: 655.53456850g/mol
- Isotope Atom Count: 7
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 2
- Heavy Atom Count: 48
- Rotatable Bond Count: 20
- Complexity: 1310
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 6
- Undefined Bond Stereocenter Count: 0
- XLogP3: 14.5
- Topological Polar Surface Area: 34.1?2
Experimental Properties
- Melting Point: N/A
- Solubility: Chloroform (Slightly), DMSO (Slightly)
- PSA: 34.14000
- LogP: 14.09740
Menaquinone 7-d7 (90%) Security Information
- Storage Condition：Amber Vial, -20°C Freezer, Under inert atmosphere
Menaquinone 7-d7 (90%) Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | M218602-0.25mg |
Menaquinone 7-d7 (90%) |
1233937-31-9 | 0.25mg |
$ 890.00 | 2023-02-02 | ||
| TRC | M218602-2.5mg |
Menaquinone 7-d7 (90%) |
1233937-31-9 | 2.5mg |
$ 8100.00 | 2023-09-07 | ||
| SHENG KE LU SI SHENG WU JI SHU | sc-489289-0.25 mg |
Menaquinone 7-d7, |
1233937-31-9 | 0.25 mg |
￥10,341.00 | 2023-07-10 | ||
| TRC | M218602-.25mg |
Menaquinone 7-d7 (90%) |
1233937-31-9 | 25mg |
$1039.00 | 2023-05-18 | ||
| SHENG KE LU SI SHENG WU JI SHU | sc-489289-0.25mg |
Menaquinone 7-d7, |
1233937-31-9 | 0.25mg |
￥10341.00 | 2023-09-05 | ||
| TRC | M218602-25mg |
Menaquinone 7-d7 (90%) |
1233937-31-9 | 25mg |
$ 1039.00 | 2023-09-07 | ||
| A2B Chem LLC | AE39261-2.5mg |
Menaquinone 7-d7 |
1233937-31-9 | 2.5mg |
$7986.00 | 2024-04-20 | ||
| MedChemExpress | HY-112499S-200μg |
Menaquinone-7-d |
1233937-31-9 | 200μg |
￥25800 | 2024-07-21 |
Menaquinone 7-d7 (90%) Related Literature
-
Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
-
Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
-
Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
-
Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
Additional information on Menaquinone 7-d7 (90%)
Research Update on Menaquinone 7-d7 (90%) and Its Applications in Chemical Biology and Medicine
Menaquinone 7-d7 (90%), a deuterated form of vitamin K2 (MK-7), has garnered significant attention in recent research due to its potential applications in metabolic studies, pharmacokinetics, and therapeutic interventions. The compound, identified by the CAS number 1233937-31-9, serves as a stable isotope-labeled analog of MK-7, enabling precise tracking in biological systems. This research brief synthesizes the latest findings on Menaquinone 7-d7 (90%), focusing on its synthesis, analytical applications, and emerging roles in biomedical research.
The synthesis of Menaquinone 7-d7 (90%) involves the selective deuteration of the isoprenoid side chain of MK-7, resulting in a compound with enhanced stability and reduced metabolic interference. Recent studies have optimized this process to achieve high isotopic purity (≥90%), which is critical for its use in mass spectrometry-based assays. The deuterated form's unique spectral properties allow for unambiguous differentiation from endogenous MK-7 in complex biological matrices, making it an invaluable tool for quantifying vitamin K2 levels in clinical samples.
In pharmacokinetic studies, Menaquinone 7-d7 (90%) has been employed as an internal standard to assess the bioavailability and tissue distribution of MK-7. A 2023 study published in the Journal of Lipid Research demonstrated its utility in tracing MK-7 absorption in human subjects, revealing significant interindividual variability in uptake kinetics. The deuterated analog's stability also facilitated the identification of novel MK-7 metabolites, shedding light on previously unexplored pathways of vitamin K2 metabolism.
Beyond its analytical applications, Menaquinone 7-d7 (90%) has shown promise in therapeutic research. Preliminary in vitro studies suggest that deuterated MK-7 may exhibit altered biological activity compared to its non-deuterated counterpart, particularly in modulating osteocalcin carboxylation and vascular calcification. These findings, though requiring further validation, open new avenues for exploring structure-activity relationships in vitamin K2 analogs.
The commercial availability of Menaquinone 7-d7 (90%) has enabled standardized protocols across laboratories, addressing previous challenges in vitamin K2 research reproducibility. However, researchers note that batch-to-batch variability in deuteration levels (typically 85-95%) necessitates rigorous quality control when employing this compound in sensitive assays. Ongoing efforts aim to further refine synthesis methods to achieve ≥95% deuteration consistently.
Looking ahead, the integration of Menaquinone 7-d7 (90%) with emerging technologies such as high-resolution mass spectrometry and microfluidic sampling platforms is expected to revolutionize vitamin K2 research. Its application in large-scale epidemiological studies may provide crucial insights into the relationship between MK-7 status and chronic diseases. Furthermore, the compound's potential as a tracer in dynamic metabolic flux analyses represents an exciting frontier for understanding vitamin K2's role in human physiology.
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
